IRB Study Number 24-421
Status Recruiting
Institute Taussig Cancer Institute
Description
Primary Objective:
To determine the feasibility and acceptability of multimodal prehabiliation during neoadjuvant chemotherapy.
Secondary Objectives:
To measure the effect of 9 weeks of prehabilitation on
- Physical function assessments pre and post NACT including:
a. 1 Rep Max Isokinetic Strength Testing
b. Grade Exercise Test (Treadmill Ramping Protocol)
c. Timed up and go
d. Grip strength
e. 30 second sit to stand
f. Unipedal stance test
Body Composition muscle mass (sarcopenia) measures and nutritional status
Patient reported outcome measures
Inclusion Criteria
1) Age 65 and older
2) Patients with diagnosis of advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) undergoing neoadjuvant chemotherapy; OR patients with diagnosis of pancreatic adenocarcinoma undergoing neoadjuvant chemotherapy. Subjects must be screened and enrolled to the study prior to the start of Cycle 2.
Exclusion Criteria
Life expectancy less than 3 months in the opinion of the treating physician
Patients unable to provide informed consent.
Wheelchair bound patients/ physical immobility.
Severe cardiopulmonary disease defined as NYHA class III or IV
Patients with malignant bowel obstruction who will require surgical intervention or nutritional support in the form of enteral or parenteral nutrition will also be excluded.
Patients with any other comorbidity or condition, which, in the opinion of the enrolling investigator, would place the patient at unnecessarily higher greater risk or burden, or if participating in the study would not be in the best interests of the patient.
